204 related articles for article (PubMed ID: 33547392)
1. Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma.
Dufies M; Verbiest A; Cooley LS; Ndiaye PD; He X; Nottet N; Souleyreau W; Hagege A; Torrino S; Parola J; Giuliano S; Borchiellini D; Schiappa R; Mograbi B; Zucman-Rossi J; Bensalah K; Ravaud A; Auberger P; Bikfalvi A; Chamorey E; Rioux-Leclercq N; Mazure NM; Beuselinck B; Cao Y; Bernhard JC; Ambrosetti D; Pagès G
Commun Biol; 2021 Feb; 4(1):166. PubMed ID: 33547392
[TBL] [Abstract][Full Text] [Related]
2. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
3. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS
Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867
[TBL] [Abstract][Full Text] [Related]
4. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
5. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
7. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.
Zhang G; Zhang Z; Liu Z
Tumour Biol; 2013 Jun; 34(3):1887-94. PubMed ID: 23494182
[TBL] [Abstract][Full Text] [Related]
9. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
[TBL] [Abstract][Full Text] [Related]
10. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
Sakurai Y; Hatakeyama H; Akita H; Harashima H
Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
12. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
13. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
14. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
15. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Rustum YM; Chintala S; Durrani FA; Bhattacharya A
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380599
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
17. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
[TBL] [Abstract][Full Text] [Related]
18. Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma.
Lee HW; Joo KM; Lim JE; Cho HJ; Cho HJ; Park MC; Seol HJ; Seo SI; Lee JI; Kim S; Jeong BC; Nam DH
Mol Cancer Res; 2013 Nov; 11(11):1375-86. PubMed ID: 23982215
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive profiling of circRNAs and the tumor suppressor function of circHIPK3 in clear cell renal carcinoma.
Li H; Heng B; Ouyang P; Xie X; Zhang T; Chen G; Chen Z; Cheang K; Lai C
J Mol Histol; 2020 Jun; 51(3):317-327. PubMed ID: 32409849
[TBL] [Abstract][Full Text] [Related]
20. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
